This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 664 studies, archived under the term: "Randomised Controlled Trial"

Click here to filter this large number of results.

Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer’s Disease Study 2
Objective: We wanted to assess if sertraline treatment (versus placebo) or remission of depression at 12 weeks (versus nonremission) in Alzheimer patients is associated with improved caregiver well being.; Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of sertraline for the treatment of depression in individuals with Alzheimer disease […]

Computerised cognitive training for older persons with mild cognitive impairment: A pilot study using a randomised controlled trial design
The results of a pilot randomised controlled trial of computerised cognitive training in older adults with mild cognitive impairment (MCI) are reported. Participants (N = 25) were randomised into either the treatment or waitlist training groups. Sixteen participants completed the 30-session computerised cognitive training program using exercises that target a range of cognitive functions including […]

Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability
Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for […]

El efecto del formato de intervención individual o grupal en la estimulación cognitiva de pacientes con enfermedad de Alzheimer. = The effect of an individual or group intervention format in cognitive stimulation of patients with Alzheimer’s disease
The study aimed to verify whether the format of an individual or group intervention, applied in a multimodal cognitive stimulation program (MCSP), had an impact on progression and behavioral disturbances associated with Alzheimer’s disease patients (AD). Forty-five participants diagnosed with probable AD were randomly divided into 3 groups. The performance of both experimental groups, receiving […]

Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n – 3 fatty acid supplementation in patients with Alzheimer’s disease: the OmegAD study
Transthyretin (TTR) binds amyloid-β (Aβ) and may reduce brain Aβ, a pathological feature in Alzheimer’s disease (AD). N – 3 fatty acids (FA), docosahexaenoic (DHA), and eicosapentaenoic acid (EPA) may increase TTR transcription in rat hippocampus. We studied effects of n – 3 FA supplementation on TTR-levels in patients with AD. Outpatients were randomized to […]

Comparing the efficacy and safety of Crocus sativus L. With memantine in patients with moderate to severe Alzheimer’s disease: A double‐blind randomized clinical trial
Objectives Limited pharmacological options are available for the management of Alzheimer’s disease (AD) in severe stages. Cognitive‐enhancing properties of saffron, the dried stigma of Crocus sativus L., have been evidenced in different studies. We aimed to compare the efficacy and safety of saffron extract versus memantine in reducing cognitive deterioration of patients with moderate to […]

A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia
Aims: The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer’s disease (AD).; Methods: Patients had probable AD and Mini-Mental State Examination scores ≥3-≤12. Primary outcome measures were as follows: Severe Impairment Battery (SIB) and AD Cooperative Study-Activities of […]

Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study
Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]

Enhancing caregiver health: findings from the resources for enhancing Alzheimer’s caregiver health II intervention
Objectives: To examine the relationships between changes from baseline to post-Resources for Enhancing Alzheimer’s Caregiver Health (REACH) intervention in caregiver (CG) self-reported health, burden, and bother.; Design: Randomized, multisite clinical trial.; Setting: CG and care recipient (CR) homes in five U.S. cities.; Participants: Four hundred ninety-five dementia CG and CR dyads (169 Hispanic, 160 white, […]

Walking the line: a randomised trial on the effects of a short term walking programme on cognition in dementia
Background: Walking has proven to be beneficial for cognition in healthy sedentary older people. The aim of this study was to examine the effects of a walking intervention on cognition in older people with dementia.; Methods: 97 older nursing home residents with moderate dementia (mean age 85.4 years; 79 female participants; mean Mini-Mental State Examination […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us